Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1245/s10434-021-11151-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correction: Nakkala et al. Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by Two Squalene Emulsion-Based Vaccine Adjuvants. 2024, , 531.
Vaccines (Basel)
December 2024
Biomedical & Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Road, Avedisian Hall, Room 480, Kingston, RI 02881, USA.
The authors would like to make the corrections described below to the published paper [...
View Article and Find Full Text PDFThe Restylane® portfolio of hyaluronic acid (HA) fillers comprises a broad range of products, each with a unique combination of gel strength/firmness and flexibility. Restylane® Shaype™ (HASHA) is a new HA injectable produced with NASHA-HD™ technology and the most recent addition to the Restylane portfolio. NASHA-HD is an evolution of the NASHA™ platform that adds more HA and uses a more efficient cross-linking even though the degree of modification is kept low.
View Article and Find Full Text PDFRecommendations on Ultrasound-Guided Hyaluronic Acid Soft Tissue Augmentation of the Upper Face in Asians.
J Cosmet Dermatol
January 2025
Department of Oral Biology, Yonsei University College of Dentistry, Seoul, Republic of Korea.
Background: Ultrasonography allows real-time imaging of facial soft tissue during hyaluronic acid (HA) filler injections. However, there is currently limited guidance relating to ultrasound-guided HA filler placement in the upper face.
Aims: To develop guidance for the effective use of ultrasonography to improve the safety of HA filler injection procedures.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Neurooncol Adv
November 2024
Huntsman Cancer Institute, Salt Lake City, UT, USA.
Background: Glioblastoma (GBM) has a median survival of <2 years. Pexidartinib (PLX3397) is a small-molecule inhibitor of CSF1R, KIT, and oncogenic FTL3, which are implicated in GBM treatment resistance. Results from glioma models indicate that combining radiation therapy (RT) and pexidartinib reduces radiation resistance.
View Article and Find Full Text PDFAssessment of the American College of Surgeons Surgical Risk Calculator (ACS-SRC) for Prediction of Early Postoperative Complications in Patients Undergoing Cytoreductive Surgery for Ovarian Peritoneal Carcinomatosis.
Curr Oncol
December 2024
Department of Digestive Surgery and Digestive Surgical Oncology, Jules Bordet Institute, The Brussels University Hospital (H.U.B), Université Libre de Bruxelles (ULB), Meylemeersch Street 90, 1070 Brussels, Belgium.
Ovarian cancer (OC) is diagnosed at a locally advanced stage in two-thirds of cases. The first line of treatment consists of cytoreductive surgery (CRS) combined with neoadjuvant and/or adjuvant chemotherapy. However, CRS can be associated with high rates of postoperative complications (POCs), and detection of fragile patients at high risk of POCs is important.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!